Top Page
Lupin Limited
(LUPIN)
Lupin Limited (LUPIN) vs. iShares MSCI India ETF (INDA)
Lupin Limited Business Overview & Revenue Model
Lupin Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 233.76B | 227.08B | 200.11B | 166.42B | 164.05B | 151.63B |
| Gross Profit | 159.68B | 153.27B | 128.99B | 94.10B | 95.05B | 94.18B |
| EBITDA | 53.87B | 50.51B | 36.27B | 15.73B | 19.66B | 25.24B |
| Net Income | 36.99B | 32.82B | 19.14B | 4.30B | -15.28B | 12.17B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 292.05B | 239.97B | 229.56B | 218.21B | 236.10B |
| Cash, Cash Equivalents and Short-Term Investments | 29.90B | 42.01B | 21.79B | 19.52B | 21.04B | 41.11B |
| Total Debt | 0.00 | 54.48B | 29.22B | 45.42B | 41.58B | 51.29B |
| Total Liabilities | -172.94B | 119.11B | 96.24B | 104.13B | 95.99B | 97.52B |
| Stockholders Equity | 172.94B | 172.03B | 142.90B | 124.64B | 121.53B | 138.03B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 13.18B | 27.19B | 3.98B | -5.38B | 11.44B |
| Operating Cash Flow | 0.00 | 30.00B | 36.48B | 18.97B | 3.67B | 18.22B |
| Investing Cash Flow | 0.00 | -41.72B | -17.12B | -12.87B | 12.92B | -12.40B |
| Financing Cash Flow | 0.00 | 17.32B | -21.84B | -3.37B | -15.72B | -18.85B |
Lupin Limited Technical Analysis
Lupin Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ₹1.05T | 18.44 | ― | 0.64% | 14.10% | 9.72% | |
| ― | ₹1.27T | 23.63 | ― | 0.83% | 6.40% | 25.27% | |
| ― | ₹893.78B | 23.70 | ― | 0.61% | 12.40% | 63.16% | |
| ― | ₹993.45B | 21.73 | ― | 1.10% | 14.52% | 9.46% | |
| ― | ₹1.22T | 60.49 | ― | 0.89% | 7.63% | 15.39% | |
| ― | ₹1.02T | 53.21 | ― | 0.04% | 21.66% | -4.92% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Lupin Limited Corporate Events
Study Overview: Lupin Limited is conducting a study titled ‘Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders From Birth to Less Than Six Years of Age Who Are Treated With Mexiletine (PEGASUS Study).’ The study aims to gather clinical and epidemiological data from pediatric patients with myotonic disorders treated with mexiletine, highlighting its significance in understanding treatment outcomes in young children.
Study Overview: Lupin Limited is conducting a study titled ‘An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR in Patients With Non-Dystrophic Myotonias (ACHILLES Study)’. The study aims to evaluate the efficacy and safety of two formulations of mexiletine, a drug used to treat myotonia, a muscle disorder. This study is significant as it could lead to improved treatments for patients with non-dystrophic myotonias.
Lupin Limited is conducting a clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2.’ This Phase 3 study aims to evaluate the safety and efficacy of Mexiletine PR in treating Myotonic Dystrophy, a significant step in addressing this rare neuromuscular disorder.
Study Overview: Lupin Limited is conducting an open-label extension study titled ‘An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed the MEX-DM-302 Study (ATLAS Study).’ The study aims to assess the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy types 1 and 2, following their participation in the MEX-DM-302 study. This research is significant as it seeks to provide a prolonged treatment option for managing myotonia symptoms in these patients.
Lupin Limited has launched an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States, aimed at managing urea cycle disorders (UCDs) in patients who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. This strategic move is expected to enhance Lupin’s presence in the U.S. pharmaceutical market, potentially increasing its market share and providing a cost-effective treatment option for patients with UCDs.
Lupin Limited announced that the U.S. FDA conducted a Pre-Approval Inspection at its Somerset, New Jersey manufacturing facility, which concluded with one observation. The company is committed to addressing the observation promptly to ensure compliance with CGMP standards, reflecting its dedication to maintaining high-quality manufacturing practices.
Lupin Limited announced that the U.S. FDA has classified its Pithampur Unit-2 manufacturing facility inspection as ‘Official Action Indicated’ (OAI) following an earlier inspection that resulted in a Form-483 with four observations. The company is actively working with the FDA to address the compliance issues and ensure adherence to CGMP standards across all its facilities. This development may have implications for Lupin’s operations and its standing in the pharmaceutical industry, particularly in the U.S. market.
Lupin Limited’s subsidiary, Nanomi B.V., has entered into a definitive agreement to acquire VISUfarma B.V., a specialty pharmaceutical company based in Amsterdam, Netherlands. VISUfarma focuses on ophthalmology and has a significant commercial presence across major European countries, offering products for dry eye, glaucoma, and other eye-related conditions. This acquisition is expected to enhance Lupin’s market positioning in the European ophthalmology sector, potentially expanding its product offerings and market reach.
Lupin Limited has announced the successful passing of resolutions via a postal ballot, including the re-appointment of Mr. Mark D. McDade as an Independent Director and a revision in the remuneration of Managing Director Mr. Nilesh D. Gupta. These resolutions, passed with the requisite majority, reflect the company’s ongoing governance and operational adjustments, potentially impacting its strategic direction and stakeholder relations.
Lupin Limited has announced that it has received approval from the U.S. FDA for its Abbreviated New Drug Application for Lenalidomide Capsules, which are bioequivalent to Revlimid® Capsules by Bristol-Myers Squibb. These capsules, intended for treating multiple myeloma and transfusion-dependent anemia, will be manufactured at Lupin’s Pithampur facility in India. The approval marks a significant milestone for Lupin, potentially enhancing its market presence in the U.S. pharmaceutical sector, given the high annual sales of Lenalidomide Capsules in the U.S. market.